• Spring Event

  • slide_prepvideos

  • Slideshow_hivhealthreform

  • Slideshow_prep

  • Slideshow_coinfection

CROI 2016: Switching to regimen with new form of tenofovir (TAF) improves kidney and bone health markers

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, 96-week results were presented from a phase 3 study that switched individuals from a regimen with the older version of tenofovir (tenofovir disoproxil fumarate, TDF) to a newer version (tenofovir alafenamide, TAF) to compare…Read More

CROI 2016: Early results show doravirine regimen as effective as efavirenz regimen

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, early 48-week results showed that the experimental NNRTI doravirine suppressed HIV levels as well as efavirenz (Sustiva) but with lower rates of side effects. No NNRTIs are currently listed as a “recommended” starting regimen…Read More

CROI 2016: New attachment inhibitor showing promise for treatment experienced patients

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, 96-week results were reported on from a Phase II study of BMS-663068 — a new class of drugs called attachment inhibitors. This type of drug works by attaching itself onto HIV’s receptor called gp120,…Read More

CROI 2016: Advances reported in long-acting PrEP

croi2016sm

A long-acting injectible version of an integrase inhibitor called cabotegravir was found to be safe in humans, according to data presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, but the injections were painful for more than half and lasted several days….Read More

CROI 2016: Serious kidney problems are rare with PrEP, but increase with older age and better adherence

croi2016sm

Three presentations at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston offered reassuring news that adverse kidney changes that accompany Truvada use for PrEP are rarely serious and universally reverse after stopping the medication, but also suggested that older people and those with…Read More

CROI 2016: Maintenance regimen of injected cabotegravir + rilpivirine advances through study

croi2016sm

At the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, early results from the LATTE-2 study were presented on a maintenance regimen of cabotegravir + rilpivirine given by injection every 4 or 8 weeks. Cabotegravir is an experimental integrase inhibitor while the oral version…Read More

CROI 2016: Breakthrough infection of man taking PrEP

croi2016sm

David Knox, MD reported at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston on the first well-described case of a gay man taking daily Truvada for PrEP becoming infected with HIV despite high adherence. It should be noted that this is the first…Read More